InvestorsHub Logo
icon url

oc631

07/30/19 4:49 PM

#225742 RE: CT #225740

I think the market has it right, the company is fairly valued at the close. The company has been buying back stock at much higher levels over the last 6-9 months and now with the reduced cash flow after the sale of Promacta this is becoming a tenuous strategy (especially if it's ego driven against short sellers). Keep in mind they no longer hold legacy tax assets after the sale.

It seems their diabetes drug is a flop. Higgins sounded like a cheerleader on the C.C. (not a good sign). Omni-Chicken will never be a leader like Captisol no matter how much he pushes that narrative. Too much competition.

One other concern going into 2020. I think their partner SAGE is a bloated pig that is going to pop (and there's a lot of bullishness built into their license agreement/relationship). I'm not current on my research of SAGE, I'm not looking to discuss it.

These are just thoughts from someone that once owned LGND stock.
icon url

jbog

07/30/19 8:17 PM

#225748 RE: CT #225740

CT,

I'm in Ligand because of their self designed Contrast Agent. They believe their Captisol design will prevent kidney damage. They just finish their phase I trials.

Having my share of MRI's and Cat scans recently I have to get a blood test each and every time prior to a scan.

Ligand having $70 bucks a share in cash doesn't hurt either.